ALLO-501’s ALPHA2 Trial Progresses but EXPAND Study Might Experience Difficulties to Enroll; ALLO-316’s AACR Results Highlighted; Allogene Ready for Partnerships to Advance its Programs; Allogene’s Q1 2023 Earnings Call Summary
On Wednesday, May 3, Allogene held its Q1 2023 earnings call (press release / presentation) highlighting the progress made in ALLO-501A’s (allogeneic CD19 CAR-T) ALPHA2 trial while admitting that some clinical trial sites have declined to participate in the EXPAND trial due to its randomized design. Below, Celltelligence provides insights on the consequences of Allogene’s decision to include ALLO-647 (anti-CD52 mAb) in its lymphodepletion regimen for the administration of ALLO-501A and its other cell therapies while discussing potential plans to partner for the development of any of its cell therapy programs.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.